IPR v. Ex Parte Reexam Strategy Considerations

Incisive. Inclusive. Invested. We’re Axinn.

Experienced, tenacious, and always trial-ready, we are committed to understanding complex legal challenges that impact the future of our clients’ businesses, globally.

Focusing on antitrust, intellectual property, and high-stakes litigation, our extensive teams in the U.S. possess deep knowledge and client-side experience across a range of sectors, including technology, healthcare, life sciences, and consumer products.

With a strong culture of diversity, equity, and inclusion, we build relationships with our clients and colleagues alike, helping communities and acting with purpose. Our client service, entrepreneurialism, and inquisitive nature sit at the heart of the firm, enabling us to prioritize client goals and achieve successful outcomes.

Explore Firm Details

Looking forward to presenting at the AIPLA IP Practice in Japan Mid-Winter Program in Houston, TX next week!

United States Intellectual Property

Jeannine Sano

I will be discussing the strategic considerations for Inter Partes Review (IPR) versus Ex Parte Reexamination, including:

The procedural differences between IPR and Ex Parte Reexamination and associated statistics
The circumstances when one may be preferable over the other
The effects of timing and estoppel in parallel litigations

My colleague, Jason Murata, another partner in Axinn's Intellectual Property group, will be covering, "Recent Developments in the Generic Pharma Industry in the U.S."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Authors

IPR v. Ex Parte Reexam Strategy Considerations

Contributor

Intellectual Property

Contributor

United States